|
WO2021062181A1
|
|
Conjugated chimeric proteins
|
|
WO2021062184A1
|
|
Pd-l1 targeted chimeric proteins and uses thereof
|
|
WO2020257412A1
|
|
Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
|
|
WO2020198665A1
|
|
Fibroblast activation protein binding agents and use thereof
|
|
WO2020198662A1
|
|
Clec9a-based chimeric protein complexes
|
|
WO2020198661A1
|
|
Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)
|
|
WO2020198654A1
|
|
Therapeutic interferon alpha 1 proteins
|
|
WO2020198659A1
|
|
Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins
|
|
WO2020132189A1
|
|
Particle based small molecule-protein complex trap
|
|
WO2020097350A1
|
|
Modulation of dendritic cell lineages
|
|
CA3108795A1
|
|
Sirp1a targeted chimeric proteins and uses thereof
|
|
AU2019243580A1
|
|
Bi-functional proteins and construction thereof
|
|
WO2019152979A1
|
|
Fibroblast binding agents and use thereof
|
|
EP3743448A1
|
|
Xcr1 binding agents and uses thereof
|
|
WO2019032663A1
|
|
Pd-1 and pd-l1 binding agents
|
|
EP3665201A1
|
|
Cd8 binding agents
|
|
BR112020002706A2
|
|
bonding agents and use thereof
|
|
CN110573172A
|
|
Targeted engineered interferons and uses thereof
|
